Method for detecting HER 2 positivity of breast cancer through ddPCR technology
A detection object and detection kit technology, applied in the field of detecting HER2-positive breast cancer using ddPCR technology
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0173] Example 1 Using ddPCR technology to detect breast cancer HER2 positive
[0174] (1) Extracting genomic DNA from tumor tissue of breast cancer patients;
[0175] Place the tissue sample on ice, cut the tissue sample the size of a grain of rice into a 1.5m1 centrifuge tube, and cut it as much as possible with a scalpel. Add 200 μl of buffer and 20 μl of proteinase K solution, and bathe in water at 56°C for more than 2 hours until the tissue is dissolved. Add 200 μl of buffer solution, mix thoroughly by inversion, and bathe in 70°C water for 10 minutes. Add 200 μl of absolute ethanol and shake fully for 15 seconds. Pour all the solution and precipitate into the adsorption column, centrifuge at 12000rpm for 30 seconds, and pour out the waste liquid in the collection tube. Add 500 μl of buffer solution to the adsorption column, centrifuge at 12,000 rpm for 30 seconds, and discard the waste liquid in the collection tube. Add 700 μl of rinsing solution to the adsorption co...
Embodiment 2d
[0184] Embodiment 2ddPCR technology detects Herceptin drug resistance
[0185]No. 1-30 breast cancer patient samples were respectively used traditional IHC and FISH techniques and the method as described in Example 1 to measure the H1 / C1, H1 / E1, H1 / E2, H2 / C1, H2 / E1, H2 / E2 value. The results are shown in the table below:
[0186]
[0187]
[0188] Among them, patients 17 and 18 were tested for circulating tumor cell CTCs after their tumors were diagnosed, and 3 and 5 CTCs were detected, respectively, of which 2 and 3 CTCs were Her2-positive, respectively. Under the advice of the doctor, the patient started to use Herceptin after the operation, and there was no recurrence after one year, and the tumor was well controlled.
[0189] In addition, patients 13, 14, 15, 16, 19, and 20 were unable to be judged as positive for Her2 by IHC and FISH techniques, so doctors did not use Herceptin for them. Using the method of the present invention, patients No. 19 and No. 20 were i...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com